Skip to content
Assyro AI
FDA Purple Book product · 351(a) biologic

Toujeo

insulin glargine

Toujeo, BLA 206538, is listed in the FDA Purple Book as a 351(a) reference biologic. This page consolidates 2 exact FDA presentation rows, and 3 FDA rows name-link 351(k) follow-on products to its reference family. It separates the BLA applicant from any unverified manufacturer and does not infer clinical labeling, pharmacy substitution, commercial availability, or patent conclusions.

351(a)BLA 206538 2 presentationsRxLicensed Sanofi-Aventis U.S. LLC
Approved
Mar 26, 2018
License type
351(a)
Marketing
Rx
Listed patents
0
Toujeo (insulin glargine) is Sanofi-Aventis U.S. LLC's FDA-licensed 351(a) biologic under BLA 206538, approved in 2018. 3 distinct approved follow-on biologics explicitly reference Toujeo (Semglee, Rezvoglar, and Langlara), making its reference-product role visible in the loaded family data.

Sourced from the FDA Purple Book · verified Oct 08, 2026

What this Purple Book record establishes

Regulatory interpretation
Ask AI

BLA number

206538

Regulatory role

351(a) reference biologic

Applicant

Sanofi-Aventis U.S. LLC

Applicant is not automatically the physical manufacturer.

Presentations

2

Exact FDA presentation rows under this BLA.

Approval

Mar 26, 2018

Follow-on biologics

3

Toujeo is a 351(a) reference biologic supported by exact-BLA evidence.

3 distinct licensed follow-on biologics in the loaded Purple Book data name Toujeo as their reference product; exact-BLA patent or exclusivity fields, or an unambiguous single-BLA name match, support this page's role.

Substitution boundary

Substitution status belongs to an individual follow-on product; it cannot be inferred from the reference product alone.

Key dates

Licensure & exclusivity
Ask AI
  1. Approval

    Approval date of this BLA submission.

    Mar 26, 2018

    8 yr 9 mo ago

  2. Today

Strengths & presentations

2 FDA presentation rows · BLA 206538
Ask AI

Strength

450UNITS/1.5ML (300UNITS/ML)

Dosage form

Injection

Route

Subcutaneous

Presentation

Autoinjector

Center

CDER

License number

1752

Product number

001

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Exact presentation matrix

One row per FDA presentation under this exact BLA. Missing cells remain unavailable rather than being borrowed from another product.

Exact FDA Purple Book presentation rows for this BLA
ProductStrengthDosage formRoutePresentationLicensureMarketing
001450UNITS/1.5ML (300UNITS/ML)InjectionSubcutaneousAutoinjectorLicensedRx
002900UNITS/3ML (300UNITS/ML)InjectionSubcutaneousAutoinjectorLicensedRx

Exact-source evidence coverage

Labeling & approval review

Current product label

Candidate awaiting exact-BLA match

FDA exposes a label link on this Purple Book row, but labeling content remains unavailable until the document is independently matched to this exact BLA and its presentations.

Inspect FDA label candidate

FDA approval evidence

Not applicable to 351(a)

A biosimilar totality-of-evidence summary is not applicable to this 351(a) record. Product-specific clinical content still requires an exact-BLA label or review source.

Human review pending

Automated BLA-level interpretation has not been marked human-reviewed. The research queue contains 1 exact-source task. Labeling and approval-review claims stay unavailable until their own match gate passes.

Reference product family

Biosimilars & interchangeables

3 distinct 351(k) follow-on biologics are linked through FDA-stated reference names to Toujeo; 3 are designated interchangeable and 3 have a licensed status in the loaded snapshot.

Exact-BLA patent, exclusivity, or unambiguous linked-family evidence supports this page's reference role. Name-linked licensed biosimilars and interchangeables are listed below.

Reference-family comparison

Purple Book comparison of products in this reference family
ProductDesignationBLAApprovedPresentationMarketing
Toujeoinsulin glargine351(a) reference biologic206538Mar 26, 2018900UNITS/3ML (300UNITS/ML) · SubcutaneousRx
Semgleeinsulin glargine-yfgn351(k) interchangeable biosimilar761201Jul 28, 20211,000UNITS/10ML (100UNITS/ML) · SubcutaneousRx
Rezvoglarinsulin glargine-aglr351(k) interchangeable biosimilar761215Dec 17, 2021300UNITS/3ML (100UNITS/ML) · SubcutaneousRx
Langlarainsulin glargine-aldy351(k) interchangeable biosimilar761412Apr 29, 2026300UNITS/3ML (100UNITS/ML) · SubcutaneousRx

Published patents

BPCIA patent list
Ask AI

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Practical characteristics and limits

Source-bounded interpretation

Presentation coverage

2 exact FDA presentation rows are consolidated under this BLA rather than split across duplicate pages.

Administration fields

The loaded rows list Subcutaneous and Injection; these are regulatory presentation fields, not dosing instructions.

Applicant boundary

Sanofi-Aventis U.S. LLC is the listed BLA applicant. The page does not relabel the applicant as manufacturer, labeler, distributor, or commercial supplier without an exact product-specific source.

Regulatory comparison

Toujeo is a 351(a) reference biologic supported by exact-BLA evidence. Family comparisons preserve each BLA's own designation and do not use Orange Book therapeutic-equivalence terminology.

Source provenance

FDA Purple Book data
Source kind · Monthly download
Checked Oct 08, 2026
FDA release · September 2026
  • advanced-searchAdvanced Search · Oct 08, 2026
  • monthly-downloadMonthly download · Oct 08, 2026
  • monthly-downloadMonthly download · Sep 21, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

What this record does not establish

  • Purple Book marketing status is a regulatory field, not real-time commercial inventory or launch status.
  • The listed applicant or BLA holder is not automatically the product’s physical manufacturer, labeler, or distributor.
  • Biosimilar status and interchangeability are distinct FDA designations; neither is a therapeutic-equivalence code from the Orange Book.
  • A missing patent or exclusivity row is not proof that no relevant rights exist, and listed patent information is not a freedom-to-operate opinion.
  • Approved uses, dosing, warnings, and clinical evidence require the exact current product label or approval package and are not inferred from the reference product.

Change history

Record versions
  • v8Oct 08, 2026
  • v7Oct 08, 2026
  • v6Sep 21, 2026
  • v5Aug 11, 2026
  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Toujeo: frequently asked questions

Licensure, biosimilar status, exclusivity, and patents for this biologic, from the FDA Purple Book.

Built directly from the FDA Purple Book database of licensed biological products. License types, approval and exclusivity dates, and the patent list match the official FDA record. The Purple Book patent list reflects the statutory BPCIA patent exchange and is not exhaustive.

Related FDA reference tools

Assyro Intelligence

Ask anything about Toujeo

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo